Micofenolato De Mofetilo Aurovitas Spain (Mycophenolate Mofetil)

• Mycophenolate Mofetil is used in immunosuppressive therapy for several transplant and autoimmune conditions.
• Kidney transplant rejection: reduces the risk of graft loss by inhibiting lymphocyte proliferation.
• Heart transplant rejection: helps maintain graft function through immune modulation.
• Lupus nephritis: diminishes renal inflammation and proteinuria in patients with active disease.

• Mycophenolate Mofetil is converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blocks de novo guanosine nucleotide synthesis in activated T and B lymphocytes, limiting their proliferation and thereby suppressing the immune response that leads to graft rejection or autoimmune tissue damage.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Gastrointestinal upset (nausea, vomiting, diarrhea)
• Headache
• Upper respiratory tract infections
• Elevated liver enzymes
• Anemia or leukopenia
• Hyperlipidaemia

Serious or Rare Side Effects

• Opportunistic infections (e.g., CMV, PCP)
• Severe neutropenia or lymphopenia
• Progressive multifocal leukoencephalopathy (PML)
• Pregnancy‑related teratogenicity
• Malignancies (especially lymphoproliferative disorders)
• Severe hepatic injury

Before initiating therapy, clinicians should assess patient suitability and monitor laboratory parameters.

• Baseline labs: obtain complete blood count, liver function tests, and renal function.
• Infection risk: screen for latent viral infections and vaccinate when appropriate.
• Pregnancy: avoid use in pregnancy; discuss contraception with women of childbearing potential.
• Renal impairment: adjust dosing or monitor closely in patients with reduced kidney function.
• Drug interactions: review concomitant medications for potential additive immunosuppression.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetilo can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Antimetabolites (e.g., azathioprine): may cause excessive bone‑marrow suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolic acid exposure.
• Live vaccines: increase risk of disseminated infection.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminium or magnesium: can lower absorption; separate dosing by at least 2 hours.
• ACE inhibitors or ARBs: may exacerbate renal dysfunction when combined.
• Cholesterol‑lowering agents (e.g., statins): monitor for additive hepatotoxicity.
• Concomitant antibiotics (e.g., trimethoprim‑sulfamethoxazole): may increase myelosuppression risk.